# To Evaluate the Efficacy and Safety of JS002 in HoFH Patients

> **NCT04515927** · PHASE2 · COMPLETED · sponsor: **Shanghai Junshi Bioscience Co., Ltd.** · enrollment: 31 (actual)

## Conditions studied

- Hyperlipemia

## Interventions

- **DRUG:** JS002

## Key facts

- **NCT ID:** NCT04515927
- **Lead sponsor:** Shanghai Junshi Bioscience Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-17
- **Primary completion:** 2022-05-06
- **Final completion:** 2022-07-29
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2024-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04515927

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04515927, "To Evaluate the Efficacy and Safety of JS002 in HoFH Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04515927. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*